Resumen

Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in countries where DAAs have not yet been approved.

Palabras clave: Peginterferon ribavirin direct-acting antivirals hyperbilirubinemia shorter treatment time.

2018-09-24   |   737 visitas   |   Evalua este artículo 0 valoraciones

Vol. 17 Núm.5. Septiembre-Octubre 2018 Pags. 756-758 Ann Hepatol 2018; 17(5)